Tuesday, 13 January 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 January 2026
News

Price cuts savage $588M in PBS revenue

Posted 13 January 2026 AM

Treatments worth $587.5 million on the R/PBS will see their price slashed by up to two-thirds at the start of February.

Bayer's blockbuster eye drug, Eylea, earned $506.1 million pre-rebate on the R/PBS for the financial year 2024-25, according to data from Services Australia, but on 1 February this year all strengths will be subject to price cuts to the published list price of 51-65 per cent.

To see the whole article, please login

Popular

New Year, new pharma on the PBS
Job moves mark start of 2026
TGA kicks off with first-in-class nod
'No deal' drugs face PBAC review
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home